Is NewAmsterdam Pharma Company N.V. Ordinary Shares a good investment? NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is currently trading at 20.14 USD. Market analysts have a consensus price target of 50.23 USD. This suggests a potential upside from current levels.
Earnings Schedule: NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to release its next earnings report on Feb. 17, 2027. The market consensus estimate for Forward EPS is -1.69.
No, it does not currently pay a dividend.
NewAmsterdam Pharma Company N.V. Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Feb. 17, 2027. The company currently has a trailing EPS of -1.69.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Community Discussion